Background: Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT-AC) has been established as the standard of care in locally advanced nasopharyngeal carcinoma (LA-NPC). The survival benefit of induction chemotherapy (ICT) for LA-NPC remains controversial. We analyzed the efficacy and feasibility of docetaxel, cisplatin and 5-fluorouracil (TPF) ICT followed by CCRT for LA-NPC with nodal Stage N2-3. Methods: We performed a retrospective analysis of 28 LA-NPC patients with nodal Stage N2-3 receiving induction TPF followed by CCRT (TPF group; n = 12) or CCRT-AC (CCRT group; n = 16) between October 2006 and May 2016. Results: The median follow-up periods were 36.4 (range 6.7-55.2) and 40.1 months (range 4.3-99.0) for the TPF and CCRT groups, respectively. One-and three-year overall survival for the TPF group vs. the CCRT group were 100% and 100% vs. 94% and 75%, respectively (P = 0.21). The cumulative one-and three-year incidences of locoregional recurrence or progression for the TPF group vs. the CCRT group were 10% and 21% vs. 16% and 32% (P = 0.49), and those of distant metastasis were 0% and 0% vs. 26% and 26%, respectively (P = 0.08). The common Grade 3-4 acute toxicities were neutropenia, anorexia, febrile neutropenia, and stomatitis in the TPF group. The Grade 3-4 late toxicities did not differ significantly between the two groups. Conclusions: This study suggests that induction TPF followed by CCRT might reduce distant metastasis, so this combination may be feasible for the treatment of LA-NPC with nodal Stage N2-3.
Introduction
Nasopharyngeal carcinoma (NPC) is a malignant tumor arising from the epithelium of the nasopharynx. It is relatively common in Taiwan, southern China and Southeast Asia, but less so in Japan (1) (2) (3) . NPC is classified into keratinizing squamous cell carcinoma (Type 1), nonkeratinizing squamous cell carcinoma (Type 2), and undifferentiated carcinoma (type 3), according to the World Health Organization (WHO) classification. Type 1 is associated with smoking, and Types 2 and 3 are strictly associated with Epstein-Barr virus (4) . The frequency of Types 2 and 3 is much higher than that of Type 1 in the south of China and Japan. The nasopharynx is located at a surgically inaccessible site, and NPC is a highly radio-and chemosensitive cancer compared with other head and neck cancers. Therefore, the development of a treatment for NPC has mainly focused on radiotherapy and chemotherapy. A randomized Phase 3 study (Intergroup 0099) clearly demonstrated that concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT-AC) had an overall survival (OS) advantage compared with radiotherapy (RT) alone in locally advanced NPC (LA-NPC) (5) . Several meta-analyses showed the superiority of CCRT-AC over RT in survival benefit in LA-NPC (6, 7) . Thus, CCRT-AC has been established as the standard of care in LA-NPC. However, treatment failure in LA-NPC treated by CCRT-AC occasionally arises due to distant metastasis, despite substantial improvement of locoregional control. Therefore, a more intensive treatment strategy, such as induction chemotherapy (ICT), is necessary for patients who have a high risk of distant metastasis. However, the survival benefit of ICT before CCRT for LA-NPC remains controversial because only one meta-analysis has reported that ICT followed by CCRT could significantly improve OS compared with CCRT alone (8) (9) (10) (11) (12) . The purpose of this retrospective study was thus to analyze the efficacy and feasibility of induction TPF followed by CCRT for patients with LA-NPC with nodal Stage N2-3, considered as a risk factor for the development of distant metastases.
Patients and methods

Patients
This study included LA-NPC patients with nodal Stage N2-3 (clinical Stage III-IVB) [ (13) (14) (15) . TPF was administered triweekly for three cycles unless progressive disease (PD) or unacceptable toxicity was observed. All patients received adequate hydration and antiemetics (dexamethasone, 5-hydroxytryptamine-3 antagonists, aprepitant). Dexamethasone was administered to prevent fluid retention and hypersensitive reactions induced by DOC. Patients were administered prophylactically the antibiotic ciprofloxacin or levofloxacin at every cycle to prevent bacterial infections. Granulocyte colonystimulating factor (G-CSF) was administered in patients with Grade 4 neutropenia or febrile neutropenia (FN); however, it was not routinely administered as prophylaxis in the first cycle of TPF.
CCRT was started within 3-6 weeks after the initiation of the final cycle of TPF for patients in the TPF group. CCRT was administered as the following regimens: triweekly CDDP (q3w; 80-100 mg/m 2 We defined the criteria for completion of TPF as follows: (1) administration of >80% of the total dose of DOC, CDDP and 5-FU; and (2) administration of more than two cycles. Similarly, the definition of completion of CCRT was as follows: (1) start of RT within 6 weeks after the initiation of the final cycle of TPF, (2) completion of 70 Gy of irradiation within 70 days, and (3) administration of chemotherapy during RT was ≥200 mg/m 2 of the total CDDP dose or ≥AUC 9.0 min mg/ml of the total CBDCA dose. Neck dissection (ND) was performed after the completion of CCRT for patients with resectable residual lymph nodes. Imaging examinations, such as CT, MRI and PET/CT, were performed every three months in the first year, every four months in the second year, and every six months thereafter until recurrence after the completion of CCRT. We followed up the subjects for five years after the completion of CCRT.
Assessment and follow-up
Statistical analysis
OS and PFS, locoregional progression-free survival (LPFS), distant metastasis-free survival (DMFS), and cumulative incidence rate were calculated by the Kaplan-Meier method. OS was calculated from the date of initial chemotherapy until death from any cause or censored at the last follow-up visit. PFS was calculated from the date of initial chemotherapy until disease recurrence, PD, death from any cause, or censored at the last follow-up visit. LPFS was calculated from the date of initial chemotherapy until recurrence in the primary tumor or a local/regional lymph node, and DMFS was calculated from the date of initial chemotherapy until distant metastasis. Survival curves and cumulative incidence curves were compared using the log-rank test, and a two-sided P value ≤0.05 was considered statistically significant. Fisher's exact test was used to compare the characteristics of the patients, cumulative toxicities and responses in the two groups, for which a P value ≤0.05 was considered statistically significant. All analyses were conducted using EZR statistical software, version 1.30 (16) .
Results
Patients
Between October 2006 and May 2016, 28 patients met the eligibility criteria for this study. Among them, 12 patients started induction TPF and 16 started CCRT-AC. The characteristics of the two groups were well balanced (Table 1) . A higher proportion of patients in both groups were at the N2 stage than at the N3 stage. All patients in both groups were staged with computed tomography (CT) and positron-emission tomography/computed tomography (PET/CT) except one patient in the CCRT group who was staged with CT alone. There was no significant difference in pre-treatment imaging methods between the two groups.
Treatment modification, clinical response and acute toxicity of induction TPF
The treatment modifications, clinical responses and acute toxicities of induction TPF are summarized in Table 2 . Induction TPF was initiated without dose reduction for all patients in the TPF group. Among 12 patients, 11 completed three cycles of induction TPF. The other patient received two cycles, and the reason for discontinuation was Grade 3 anorexia. Dose reductions of the second cycle of induction TPF were required for seven patients (58%). The reasons for dose reductions were Grade 4 neutropenia (n = 3), Grade 3 FN (n = 3) and Grade 3 stomatitis (n = 1) during the first cycle of induction TPF. G-CSF was used for 11 patients (92%) during induction TPF. Overall, treatment modification of the TPF regimen was required in eight patients (67%).
All patients met the criteria for the completion of induction TPF. Response after induction TPF was evaluated after the last cycle of TPF. Complete response (CR) or partial response (PR) was achieved in all patients (12/12) .
The common Grade 3-4 acute toxicities were neutropenia (n = 11), anorexia (n = 4), FN (n = 4) and stomatitis (n = 2). No treatment-related deaths occurred.
Treatment modification, clinical response and acute toxicity of CCRT
The methods of delivery, clinical responses and acute toxicities of CCRT are summarized in Tables 3 and 4 . All patients treated with induction TPF received subsequent CCRT.
All patients were given once-daily fractionated radiation (2 Gy/ day for 5 days/week). There were no differences in the duration or dosage of RT administration between the two groups. Regarding the technique used, all patients in both groups received IMRT, except for four patients in the CCRT group. The planned RT dose was delivered in all patients in both groups. Triweekly CDDP (80-100 mg/m 2 ) was routinely administered in the CCRT group (n = 14, 88%), except for two patients treated with weekly CBDCA owing to renal dysfunction. Of 14 patients receiving triweekly CDDP in the CCRT group, initial dose reduction was required in three patients (CDDP 80 mg/m 2 ) and subsequent dose reduction through all cycles was required in 11 patients (79%). The reasons for dose reduction were Grade 4 neutropenia (n = 1), Grade 3 FN (n = 1), renal dysfunction (n = 4), hepatotoxicity (n = 1), anorexia (n = 1), hearing impairment (n = 1), overweight (n = 1). In addition, the dose of CDDP in the first cycle was reduced in one patient, because administration of dexamethasone as antiemetic was omitted in consideration of gastric ulceration induced by endoscopic submucosal dissection conducted for early gastric cancer just before CCRT was initiated. All patients in the CCRT group met the criteria for the completion of CCRT. Regarding the subsequent CCRT regimens in the TPF group, however, split CDDP and weekly CDDP were used in two and four patients, respectively, in consideration of their renal dysfunction, myelotoxicity, and gastrointestinal disorders. Among six patients receiving triweekly CDDP in the TPF group, reduction of the initial dose was required in two patients (CDDP 80 mg/m 2 ).
One patient switched to triweekly CBDCA after the first cycle of triweekly CDDP due to increased creatinine, and one patient received split CDDP after the first cycle of triweekly CDDP due to ) in the CCRT group (n = 16). There were no differences in the patients who met the criteria for CCRT completion between the two groups (75% vs. 100%, P = 0.07) ( Table 3) . Evaluation of the response after CCRT revealed that CR and PR were observed in 12/12 (100%) and 15/16 (94%) of patients in the TPF and CCRT groups, respectively. The CR rate for the TPF group vs. the CCRT group was 92% vs. 31%, with a significant difference between them (P = 0.002) ( Table 3) . Criteria for completion of TPF were as follows: (1) administration of >80% of the total dose of docetaxel, cisplatin and 5-fluorouracil; (2) administration of more than two cycles. Criteria for completion of CCRT: (1) initiation of RT until six weeks after the start of the final cycle of TPF; (2) completion of 70 Gy of irradiation within 70 days and (3) chemotherapy administered during RT was ≥200 mg/m 2 of total CDDP dose or ≥ AUC 9.0 min·mg/ml of total CBDCA dose. Patients in the TPF group fulfilled all criteria, and those in the CCRT group fulfilled criteria (2) and (3).
Of 16 patients in the CCRT group, 12 received AC after CCRT, such as CDDP and 5-FU (n = 10), CBDCA and 5-FU (n = 1), and S-1 alone (n = 1). The reasons why four patients did not receive AC included Grade 3 stomatitis (n = 1), high age (n = 1), infection (n = 1), aspiration pneumonia (n = 1). No patients in the TPF group received AC. While no patients in the TPF group received salvage ND, of 10 patients who achieved PR in the CCRT group, 2 underwent salvage ND for residual lymph nodes. There was no significant difference in Grade 3-4 acute toxicities during CCRT between the two groups, except for anorexia (TPF group vs. CCRT group: 33% vs. 75%, P = 0.05) ( Table 4) .
Survival rate
Median follow-up periods were 36.4 (range 6.7-55.2) and 40.1 (range 4.3-99.0) months for the TPF and CCRT groups, respectively. Median PFS was not reached and 35.4 months for the TPF and CCRT groups, respectively (Fig. 1) ; median OS was not reached in both groups (Fig. 2 ). There were trends for improvement of the one-and three-year OS and one-and three-year PFS in favor of the TPF group compared with the CCRT group (OS: 100% vs. 94%, and 100% vs. 75%, P = 0.21; PFS: 90% vs. 69%, and 79% vs. 50%, P = 0.11, respectively) (Fig. 2) . The cumulative one-and three-year incidence rates of locoregional recurrence or progression for the TPF group vs. the CCRT group were 10% vs. 16%, and 21% vs. 32%, respectively (P = 0.49) (Fig. 3) . The cumulative incidence of locoregional recurrence or progression in the TPF group was comparable to that in the CCRT group. In contrast, the cumulative one-and three-year incidence rates of distant metastasis in the TPF group were substantially lower than those in the CCRT group (0% vs. 26%, and 0% vs. 26%, respectively; P = 0.08) (Fig. 4) . There was a trend for improvement of the one-and three-year DMFS in favor of the TPF group compared with the CCRT group (100% vs. 74%, and 100% vs. 74%, P = 0.08, respectively; data not shown).
Late toxicity
Late toxicities are shown in Table 5 . Four patients (33%) in the TPF group and six patients (38%) in the CCRT group had Grade 3-4 late toxicities. The rate of any grade hypothyroidism was significantly higher in the TPF group than in the CCRT group (TPF group vs. CCRT group; 58% vs. 13%, P = 0.02). On the other hand, the rate of any grade laryngeal edema was significantly higher in the CCRT group than in the TPF group (TPF group vs. CCRT group; Peripheral sensory neuropathy. Figure 1 . Kaplan-Meier plot shows progression-free survival of patients in the TPF and CCRT groups (n = 28). There was a trend for improvement of progression-free survival in favor of the TPF group (log-rank P = 0.11). TPF, docetaxel, cisplatin and 5-fluorouracil; CCRT, concurrent chemoradiotherapy; PFS progression-free survival.
0% vs. 31%, P = 0.05). There was no significant difference in Grade 3-4 late toxicities between the two groups. One patient died of temporal lobe necrosis three years after CCRT in the TPF group.
Discussion
In clinical practice, the addition of ICT to CCRT has been investigated to improve OS through the control of both locoregional and distant metastasis in LA-NPC. However, whether the addition of ICT to CCRT is superior to CCRT-AC remains controversial for LA-NPC. Our retrospective study investigated whether induction TPF could reduce the risk of distant metastases and consequently improve OS in patients with LA-NPC with nodal Stage N2-3. OS and DMFS showed trends toward better improvement in induction TPF followed by CCRT compared to CCRT with or without AC. Furthermore, our results showed a longer survival time than that reported in two Phase 2 trials using induction TPF for LA-NPC (17, 18) . All patients in the TPF group met the criteria for the completion of induction TPF. Although the TPF group had significantly higher CR rate than the CCRT group (Table 3) , the TPF group had less locoregional control than CCRT group (Fig. 3) . This discrepancy may be partially because of relatively low CCRT completion in the TPF group compared with the CCRT group (Table 3) . These results suggest that induction TPF followed by CCRT is well tolerated and may reduce distant metastasis in LA-NPC with nodal Stage N2-3, although the survival benefit of ICT still remains controversial.
Three randomized Phase 2 trials have compared ICT followed by CCRT with CCRT alone in Stage III-IVB NPC (19) (20) (21) . A randomized Phase 2 trial using ICT with DOC and CDDP in Stage III-IVB NPC showed that the three-year OS for ICT followed by CCRT vs. CCRT alone was 94% vs. 68% (P = 0.01), suggesting the survival benefit of ICT in patients with advanced NPC (19) . However, two randomized Phase 2 trials using ICT with CDDP, epirubicin and paclitaxel (PTX) or with gemcitabine, CBDCA and PTX in Stage IIB-IVB NPC demonstrated no difference in OS and PFS between ICT followed by CCRT and CCRT alone (20, 21) . Several factors may explain these inconsistent results in the above trials. The ICT regimens used in these trials were powerless to lead to survival benefit of ICT over CCRT alone. Furthermore, the above trials might have included some patients for which ICT was originally unnecessary.
Taking the above evidence into consideration, two major recommendations regarding our treatment strategy for LA-NPC were Figure 2 . Kaplan-Meier plot shows overall survival in the TPF and CCRT groups (n = 28). There was a trend for improvement of overall survival in favor of the TPF group (log-rank P = 0.21). OS, overall survival. Figure 3 . Cumulative incidence of locoregional recurrence or progression for TPF vs. CCRT groups (n = 28). Cumulative incidence of locoregional recurrence or progression for the TPF group was comparable to that for the CCRT group (log-rank P = 0.49). CCRT groups (n = 28). Cumulative incidence of distant metastasis for the TPF group was lower than that for the CCRT group (log-rank P = 0.08).
revealed. The first was the validity of using a more powerful ICT regimen for LA-NPC. Two recent single-arm Phase 2 trials in patients with Stage III-IV NPC who received induction TPF followed by CCRT showed that the three-year OS was 86-95% (17, 18) . However, two Phase 3 trials in patients with Stage III-IV NPC who received CCRT-AC reported that the three-year OS was 78-86% (22, 23) . These results may suggest that TPF is a promising regimen as ICT for LA-NPC. However, induction TPF frequently induced myelotoxicity in patients with locally advanced head and neck squamous cell carcinoma (24, 25) . Indeed, in the present study, Grade 3-4 neutropenia and FN frequently occurred during induction TPF. Although their toxicities were manageable with prophylactic antibiotics and G-CSF, such a toxic regimen should only be applied to selected patients with LA-NPC in clinical practice, taking the above toxicities into consideration.
The second recommendation was to select specific subgroups in Stage III-IV NPC who have a relatively high risk of distant metastases. CCRT with or without AC may be inadequate for certain highrisk patients with LA-NPC, and several studies have demonstrated that patients with nodal Stage N2-3 NPC have a higher risk of distant metastases than nodal Stage N1 NPC (26) (27) (28) . Therefore, we specifically targeted N2 and N3 cases with a high risk of distant metastasis, excluding N1 NPC, in our study.
A recent Chinese Phase 3 randomized trial reported that induction TPF followed by CCRT could significantly improve failure-free survival, OS, and distant failure-free survival compared with CCRT alone in patients with Stage III-IV NPC with nodal Stage N1-3 (29) . The reasons for these positive results may be that TPF as ICT was a powerful regimen and this trial excluded T3-T4N0 NPC patients who had a considerably low risk of distant metastasis. However, high-dose triweekly CDDP as the CCRT regimen was routinely administered after induction TPF and sufficient information on late toxicity was unavailable. The NCCN guidelines version 2.2016 for head and neck cancers do not recommend using highdose triweekly CDDP-based CCRT after a CDDP-based ICT regimen due to late toxicity concerns, such as renal dysfunction, hearing impairment and neuropathy. After a CDDP-based ICT, cetuximab plus RT can be an option in the treatment of squamous cell carcinoma of head and neck (30) . However, there is no sufficient evidence of cetuximab plus RT for treatment of LA-NPC. Therefore, we switched to administering weekly CDDP and weekly CBDCA instead of high-dose triweekly CDDP as the CCRT regimen after induction TPF in consideration of late toxicity. Our follow-up of late toxicity demonstrated no differences in Grade 3-4 between the two groups. In addition, although the Chinese Phase 3 trial excluded those aged 60 years or more for safety reasons, our study suggested that induction TPF followed by CCRT was feasible even for elderly patients. We hope that a Phase 3 randomized trial (NCT00828386) for which registration has already been completed will clarify the above issues.
The current study has certain limitations, such as the small number of patients, use of retrospective data and performance at a single center, and the follow-up periods were too short to assess OS and late toxicity. In addition, because this study mainly compared induction TPF followed by CCRT with CCRT-AC, a pure treatment effect of induction TPF for LA-NPC was not demonstrated.
In conclusion, induction TPF followed by CCRT may be a feasible option in the treatment of LA-NPC with nodal stage N2-3. In the future, appropriate selection of patients who are able to obtain a greater survival benefit by the addition of induction TPF to CCRT may be required in Stage III-IV NPC. A longer follow-up will also be needed to assess OS and late toxicity sufficiently. 
